1 | cd /media/ht/ht_5T/Work/Funding/2017_重大专项/Management/Closing/Summary/Print/Tech |
1 | Dir=uniprot |
尝试新的跨平台 PowerShell https://aka.ms/pscore6
1 | i='/media/ht/ht_5T/Stored_Softs/Windows_Installer/Win_activate' |
算命软件是集八字算命软件、姓名算命软件、周易算命软件、星座算命软件、风水算命软件等于一体的综合算命软件。手机安卓算命软件哪个好,算命软件哪个最准最全？历趣网悉心整理了手机安卓算命软件排行榜、免费算命软件手机版。历趣小编为大家推荐最流行的算命软件。
准了app2021-04-08__生活 / 55.3MB下载
灵占天下八字算命20212021-06-01__娱乐 / 100MB下载
紫微大师app2021-05-15__生活 / 153MB下载
文墨天机紫微斗数app2021-04-30__生活 / 21.4MB下载
1518占卜大师app2019-05-17__娱乐 / 1.72MB下载一个手机占卜应用，解梦、测试，随时随地占卜测算,属于您的私人掌上神算子。
奇门遁甲排盘软件手机版2020-11-04__生活 / 27.5MB下载2018-03-16 15:20:26苏叶下载之家
手机查看
新的一年到来，对喜欢算命的朋友来说，有的就想知道自己再2018年运势如何？当然，时代的进步，网上也是出现了各种各样的算命软件。那么，有朋友就在问小编：什么算命软件准？针对这个问题，小编今天就给大家带来几个手机算命软件，以供大家参考。
周易算命宝
周易算命宝是一个为用户提供生辰八字算命，八字合婚测试以及周公解梦大全查询的APP。八字算命-提供八字命盘、五行分析、八字论命、爱情事业、财运健康查询。八字合婚-提供夫妻命宫、夫妻缘分以及双方的默契、相旺与子女同步查询。周公解梦-将原版周公解梦大全结合现代文字表述，附以案例分析让用户更加清晰了解梦境内外所关联的原因。
下载地址：周易算命宝安卓版
紫微斗数
紫微斗数app这是一款关于命理学紫薇都数的应用，紫微斗数app通过黄道12宫来对应每个人的每一种生命特质，紫微斗数app基于此来推算一个人命理，当然紫微斗数app这是一款免费的软件，信则灵，不信则不灵。
软件介绍
紫微斗数app港澳台著名影星江美仪鼎力推荐、着名玄爱本应用作为「灵机」品牌下的紫微斗数命理学代表，由大陆、香港和台湾多位专业紫微大师携手合作，致力打造最先进最准确的紫微排盘命理应用，是苹果市场上最专业最准确的测算类应用。
紫微斗数app是香港风水天后麦玲玲、香港风水命理人气王李丞责、香港着名玄学家陈定邦、香港大学进修学院玄学家何汉明、中国岭南地区着名风水命理大师何树荣、台湾面相改运第一人罗镇等众多命理界一级大师均表明对灵机的认可和支持！
下载地址：紫微斗数安卓版
紫微大师星座算命
不是所有人都有幸遇到紫微大师指点，每一秒一个用户加持中。你是下一个幸运儿？性格分析，心理测试，塔罗，生辰八字，星座算命，命理占卜，生肖配对，姓名日历，周易风水，求签六爻卦，相面手相，八卦易经综合预测第一平台。
软件特色
全球紫微斗数APP论命排名第一；
学习紫微斗数第一必备工具；
鼻祖传人30年首次公开单传秘笈算法；
大数据时代500万科学统计验证准确率100%；
宝典级婚恋、职场、商场、创富攻心神术；
100多个问题解盘人生百态事强大自我助梦成功；
铁断结婚、离婚、小三、创业、升迁、暴富、怀孕年份；
帮您30岁前知天命带着棋谱下棋绝杀 九大版块；
命盘：运用销量第一的紫微排盘王app帮你专业排出命盘；
解盘：40多个问题宫位对应一一帮你全局分析一生；
紫微占卜：80多个问题帮你占卜流年、流月、流日遇事的各种问题；
运势解码：根据独家创世能量体系每年、每月、每日能量运势一目了然吉凶可见；
下载地址：紫微大师星座算命安卓版
灵机妙算
灵机妙算为你解读流年运程，流月运程，生肖运程，八字命理，提供最专业精准的性格分析、事业分析、健康分析、婚恋分析助你新的一年万事如意。还有著名易学导师撰写的转运方法，命运的走势有其自身的规律，只要掌握规律，命运就会转变。最专业精准的周易、八字、紫微斗数指导人生规则，星座运程提供每天十二星座运程信息。
下载地址：灵机妙算安卓版
灵机算命占卜大师
灵机算命占卜大师预测，事业、财运、学业、健康、拜访、占一卦知进退，万事如愿以偿。别感叹命运不公，知命，改运有秘诀！今日运势如何？未来的婚姻如何？财运如何？适合买吗？股票会不会涨？何时买房子？事业进展？彷徨，迷茫，犹豫，人生十字路口，如何抉择？尽在灵机算命占卜大师！
下载地址：灵机算命占卜大师安卓版
算命八字风水罗盘
八字排盘是中国人民传统文化的结晶，经历几千年的岁月而沉淀下来，具有丰富的科学理论，是经过科学鉴证的解说命理工具。八字排盘提供算命，为您通晓未来，让你为接下来的未来做好充分的准备。
功能介绍
1、八字算命：命理老师亲自指导，看排盘，周易占卜测算，为您专业提供命理信息；
2、运程分析：大运年表、流年运程为您分析一生运程起伏，流年趋吉避凶。十神、命宫详解让您知晓先天运势、命运的主轴、行运的源头。
3、婚恋配对：看桃花，定姻缘，帮你找到身边的那个TA；
4、命主分析：性格、事业、星座分析全面独到，预测您人生的贫贱富贵，让您更了解自己。
5、健康养生：提供养生要点，为您调整饮食和生活起居，助您保持健康。 在搜索查找播放器，聊天，漫画，导航，新闻，阅读，FM，天气，无秘，宝宝助手，微代驾，双色球，妈妈帮，辣妈帮，周公解梦的应用，还不如解开自己八字秘密。
下载地址：算命八字风水罗盘安卓版
算命八字运程大师
算命八字运程大师是一款专业的八字算命占卜应用，从八字剖析运势发展！
应用特色：
1 八字算命：全面测算一个人的八字命盘，姻缘桃花，手相算命，事业财富。
2 八字婚姻：按生辰八字来算命，按脸相手相算命，姻缘测算。
3 星座运势：十二星座运程每周更新，星座每日运势，每周运势，每月运势。
4 风水占卜：通过周易风水占卜，提供占卜参考。
下载地址：算命八字运程大师安卓版
神算宝典
神算宝典app是一款极具中国风特色的真人在线预测应用，神算宝典app从浩如烟海的易学典籍中去伪存真，依托几千年来无数前贤继承发展的易经文化及其他预测方法，实现在易学专家的指导下，使人能够做到预知祸福，趋利避害。
功能介绍
1.神算解卦：多位大师为您解卦，并指引明路，从此富贵贫贱不再神秘，吉凶祸福不必烦恼。
2.运势锦囊：运势缥缈无踪迹，一道谜题破玄机。打开锦囊将获得一道谜题，参透谜题可了解近期个人运势，趋吉避凶。
3.合姻生肖：查看三个隐藏在卡牌中的生肖，配对您的最佳伴侣，开启一世美好姻缘！
4.周公解梦：用周易卜卦的方法，推算此阶段的旺衰状态，推定梦象的吉凶，旺者吉，衰者凶，你属于哪种呢？
5.天机测算：掐指一算天机现，所求何事，让诸葛丞相为您卜一卦，祝您事事顺风顺水！
6.婚恋吉日：做事挑个好日子，百事吉利，万事如意。
1 | cd /media/ht/ht_5T/Work/Funding/2021_十四五/Guidances/MOST # 李颖下载 |
票据打印，个别需要封面
https://m.ebiotrade.com/newsf/2020-9/2020918102849449.htm
http://www.detaibio.com/topics/antibody-purifications/chromatography-methods.html
http://blog.sciencenet.cn/blog-454912-713842.html
1 | setsid chromium-browser \ |
1 | setsid chromium-browser \ |
October 4, 2018 | ByMeryl Kremer|ORP
You may have heard of ORP, but what does it mean and what role does it play in water-quality testing? We’ve laid out the basics of ORP to help you get up to speed.
Also check out our deep dive into ORP’s role in water contamination inthis post, andWater Quality 101: What is pH in Water Testing.
Oxidation reduction potential, or ORP, is a measure of a substance’s ability to either oxidize or reduce another substance. It is measured by the electrodes of an ORP meter. A positive reading on an ORP meter means that the substance is an oxidizing agent; a negative reading indicates that the substance is a reducing agent.
If a substance doesn’t have enough electrons, it will actively attempt to acquire them through the process of oxidation—a chemical reaction in which one agent is oxidized (i.e., loses electrons to another agent). Because substances with positive ORP readings are looking to acquire electrons, they are considered oxidizing agents.
On the other hand, electrons that have a surplus of ions can afford to lose ions to oxidizing agents without becoming destabilized themselves. For this reason, they are referred to as antioxidizing agents, or reducing agents. The higher or lower an ORP reading (positive or negative), the more oxidizing or antioxidizing a substance is, respectively.
ORP is integral to water testing because it indicates how sanitized or contaminated water is based on its oxidation and reduction properties. In order to be safe to consume, recycle, or come in contact with our skin, water is treated with a sanitizing agent to have a higher oxidation potential, producing a higher ORP reading. By routinely monitoring ORP levels, it’s possible to monitor the effectiveness of a sanitizing agent and adjust your water treatment plan accordingly.
There are many reasons why someone would be interested in knowing the ORP of a substance. Perhaps the most common application is water-quality testing of chlorinated swimming pools. Because a substance’s ORP is affected by all agents that are present in the substance, an ORP measurement is considered more informative than a pH reading alone, which only recognizes acids (hydrogen ions) and bases (hydroxide ions). Larger pools will often have inline ORP sensors, whereas backyard pools that lack built-in monitors may require testing with a portable ORP monitor.
When you add chlorine to a pool, the chlorine gives up its own electron surplus to neutralize or oxidize potentially harmful bacteria. Active chlorine electrons increase the ORP level of the water, thus neutralizing contaminants. For chlorinated pools and spas, a safe ORP reading is usually between 650 millivolts (mV) and 750 mV. As time passes and chlorine breaks down and loses its oxidation potential, the overall ORP reading for the water gradually decreases. Although ORP levels typically correlate with the ratio of sanitizer in the water, ORP does not measure sanitizer levels; rather, it measures the net oxidation and reduction properties of all agents present.
In addition to being used to monitor water quality in chlorinated pools, ORP meters are widely used in the food processing and water treatment industries to ensure that water is free of contaminants and safe to recycle or consume. Bottled water or tap water that is contaminant-free will have a positive ORP value.
When it comes to swimming pools, ORP levels can usually be adjusted by adding more active chlorine to the water to boost its antioxidizing potential. More sophisticated water purification systems may involve a more complex balancing of total dissolved solids (TDS) in water to achieve a more favorable oxidation reduction potential.
For more information about how to interpret ORP readings and use ORP meters, research your chosen ORP meters and its unique features.
Interested in purchasing a mobile or inline ORP meters? Click the button below to learn about different models and features and find a distributor.
keyword, antibody purification
https://patents.google.com/patent/KR101243425B1/en?q=antibody+purification&oq=antibody+purification
KR101243425B1
1 | setsid chromium-browser \ |
1 | TZ=GMT date -d '2017-01-29 08:58:09 CST' +'%F %T %Z' |
1 | # QV2Ray |
1 | setsid chromium-browser https://merlinblog.xyz/wiki/freess.html https://www.facebook.com/groups/139561307215714/ https://sites.google.com/site/ssrandv2rayandss/zui-xin-mian-fei-shou-feiv2ray-ding-yue-de-zhi https://raw.githubusercontent.com/ssrsub/ssr/master/v2ray https://qv2ray.net/lang/zh/getting-started/step3.html#%E5%88%86%E4%BA%AB%E9%93%BE%E6%8E%A5 https://appimage.github.io/Qv2ray/ https://qv2ray.net/getting-started/step2.html#download-v2ray-core-files https://github.com/v2fly/v2ray-core/releases https://www.v2fly.org/guide/start.html#%E5%AE%A2%E6%88%B7%E7%AB%AF https://github.com/v2fly/v2ray-core/releases https://tracker.debian.org/pkg/golang-v2ray-core https://flathub.org/apps/details/com.github.Qv2ray https://github.com/Qv2ray/qv2ray.github.io chrome://downloads/ |
Primary outcome measure
In a clinical study’s protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Secondary outcome measure
In a clinical study’s protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
First submitted that met QC criteria
The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM’s QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
This glossary will help you understand words and phrases frequently used on ClinicalTrials.gov. Many of these words are also used by clinical researchers and others in the same or a similar manner. But the definitions below are provided to explain content on ClinicalTrials.gov only.
For help with medical terms, see the MedlinePlus® Medical Encyclopedia.
Study record managers should refer to the Protocol Registration Data Element Definitions, Expanded Access Data Element Definitions, and Results Data Element Definitions for help with the data items required to register a study and submit results using the ClinicalTrials.gov Protocol Registration and Results System.
The age groups are:
* Child (birth-17)
* Adult (18-64)
* Older Adult (65+)For more information, see FDA Expanded Access: Information for Patients.
The National Library of Medicine (NLM) is required by FDAAA 801 to add information to a study record about any FDAAA 801 Violation. This information is provided by the FDA. There are three categories of information that may be included:
* Violation: Shown when the FDA issues a Notice of Noncompliance and posts the Notice of Noncompliance on its designated webpage. There are three types of violations:
* Failure to submit required clinical trial information
* Submission of false or misleading clinical trial information
* Failure to submit primary and secondary outcomes
* Correction: Shown when the FDA confirms that the responsible party has updated the study record to correct the violation and posts the correction notice on its designated webpage. Because of the time for FDA review and processing, there may be a delay between the date when the study record was updated and the addition of correction information to the FDAAA 801 Violation information.
* Penalty: Shown when the FDA imposes a penalty for the violation and posts the penalty notice on its designated webpage.For more information, see Participating in Studies on this site.
For more information, see Participating in Studies on this site.
A patient registry is a type of observational study.
Note: The ClinicalTrials.gov results database became available in September 2008. Older studies are unlikely to have results available in the database.
The results submitted date indicates when the study sponsor or investigator first submitted summary results information or submitted changes to summary results information. Submissions with changes are typically in response to QC review comments from the National Library of Medicine (NLM). If there is a date listed for results submitted to ClinicalTrials.gov, but there is not a subsequent date listed for results returned after quality control review , this means that the submission is pending review by NLM.
mermaid1 | cat HIV_ClinicalTrials.tsv | awk -F'\t' '{print $5}' | sort | uniq |
Effectiveness of Antiretroviral Therapy During Acute HIV Infection
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00705926
Recruitment Status : Completed
First Posted : June 27, 2008
Last Update Posted : August 31, 2017
Sponsor:
Massachusetts General Hospital
Collaborator:
National Institute of Allergy and Infectious Diseases (NIAID)
Information provided by (Responsible Party):
Eric Rosenberg, MD, Massachusetts General Hospital
Study Description
Go to 
Brief Summary:
This study will determine whether HIV treatment that is initiated during the acute phase of HIV infection, followed by discontinuation of treatment, is effective in reducing the amount of HIV and an increasing the amount of CD4 cells in the blood of people with HIV, compared to the amounts of HIV and CD4 cells in people who do not receive treatment at this stage.
Condition or disease
Intervention/treatment
Phase
HIV Infections
Drug: Highly Active Antiretroviral Therapy (HAART)Other: No treatment
Phase 1
Detailed Description:
Antiretroviral (ARV) therapy for the treatment of HIV infection has been remarkably successful in reducing morbidity and mortality in HIV infected people. This treatment still has its shortcomings, however. Individuals receiving ARV treatment are at risk of toxicity, developing drug resistance, and unknown long-term side effects. Therefore, development of alternative treatment strategies is important. A short course of ARV treatment that is initiated during the acute period of HIV infection, followed by treatment cessation may have a substantial impact on controlling infection and delaying the need for lifelong potent ARV therapy. The purpose of this study is to investigate whether treatment initiated during acute HIV infection and followed by a terminal treatment interruption is effective in lowering the viral load set point and raising CD4 cell counts in people with HIV, as compared to those measures in people with HIV who have received no treatment.
Participants in this study will be randomly assigned to one of three groups. Participants in Group A1 will receive ARV therapy for 12 weeks. Participants in Group A2 will receive ARV therapy for 32 weeks. Participants in Group B will not receive any treatment. This study will not provide medications to any of the groups. All groups will be followed for a total of 72 weeks following study entry. Participants will attend between 30 and 36 study visits over the course of the 72 weeks, depending on their study group. Study visits will occur every week for the first 12 weeks and then every 1 to 6 weeks for the remainder of the study. Tests occurring at study visits may include blood tests, investigational immune system tests, and pregnancy tests. Participants will also undergo a complete physical exam and will be asked to provide information about their medical and medication histories.
Study Design
Go to
Study Type :
Interventional (Clinical Trial)
Actual Enrollment :
25 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
A Phase 1 Clinical Trial to Evaluate the Initiation of Treatment Versus no Treatment During Acute HIV-1 Infection
Study Start Date :
October 2008
Actual Primary Completion Date :
February 7, 2013
Actual Study Completion Date :
July 16, 2017
Resource links provided by the National Library of Medicine
MedlinePlus related topics: HIV/AIDS
Arms and Interventions
Go to
Arm
Intervention/treatment
Experimental: A1
Antiretroviral therapy followed by discontinuation at Week 12.
Drug: Highly Active Antiretroviral Therapy (HAART)
Participants in Groups A1 and A2 will receive HAART for either 12 or 32 weeks. Their medications will not be provided by the study.
Experimental: A2
Antiretroviral therapy followed by discontinuation at Week 32.
Drug: Highly Active Antiretroviral Therapy (HAART)
Participants in Groups A1 and A2 will receive HAART for either 12 or 32 weeks. Their medications will not be provided by the study.
Placebo Comparator: B
No treatment.
Other: No treatment
Participants in this group will not receive treatment at this stage of their infection.
Outcome Measures
Go to
Primary Outcome Measures :
Secondary Outcome Measures :
Difference in the level of CD4 cells if therapy is initiated during acute HIV infection followed by terminal treatment interruption after 12 or 32 weeks of treatment compared to that under no treatment [ Time Frame: Week 72 ]
Difference in the level of HIV RNA and CD4 cell numbers between therapy initiated during acute HIV infection followed by terminal treatment interruption after at least 12 weeks of treatment and no therapy at 16 weeks after discontinuation of treatment [ Time Frame: Weeks 12 and 16 ]
Difference in the level of HIV at viral load set point and CD4 cell number at 72 weeks after study entry if therapy is initiated during acute HIV infection followed by terminal treatment interruption at 12 weeks versus at 32 weeks [ Time Frame: Week 72 ]
Eligibility Criteria
Go to
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years to 65 Years (Adult, Older Adult)
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Criteria
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations
Go to
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00705926
Locations
United States, Massachusetts
Massachusetts General Hospital
Boston, Massachusetts, United States, 02114
Sponsors and Collaborators
Massachusetts General Hospital
National Institute of Allergy and Infectious Diseases (NIAID)
Investigators
Study Chair:
Eric S. Rosenberg, MD
Massachusetts General Hospital, Division of Infectious Diseases
Principal Investigator:
H.T. Banks, PhD
North Carolina State University, College of Physical and Mathematical Sciences
Principal Investigator:
Marie Davidian, PhD
North Carolina State University, Department of Statistics
More Information
Go to
Publications:
Responsible Party:
Eric Rosenberg, MD, Investigator of Record, Massachusetts General Hospital
ClinicalTrials.gov Identifier:
NCT00705926 History of Changes
Other Study ID Numbers:
R01AI071915 ( U.S. NIH Grant/Contract )
RO1AIO71915 ( Other Grant/Funding Number: NIAID )
First Posted:
June 27, 2008 Key Record Dates
Last Update Posted:
August 31, 2017
Last Verified:
August 2017
Keywords provided by Eric Rosenberg, MD, Massachusetts General Hospital:
Acute Infection
HIV
HAART
Treatment Naive
Additional relevant MeSH terms:
HIV Infections
Acquired Immunodeficiency Syndrome
Infection
Communicable Diseases
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Virus Diseases
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Immunologic Deficiency Syndromes
Immune System Diseases
Slow Virus Diseases
Anti-Retroviral Agents
Antiviral Agents
Anti-Infective Agents
Research on Effect of Traditional Chinese Medicine (TCM) on Immune Reconstitution of HIV/AIDS Patients After Highly Active Antiretroviral Therapy (HAART)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00974454
Recruitment Status : Unknown
Verified September 2009 by Guang’anmen Hospital of China Academy of Chinese Medical Sciences.
Recruitment status was: Recruiting
First Posted : September 10, 2009
Last Update Posted : October 29, 2009
Sponsor:
Guang’anmen Hospital of China Academy of Chinese Medical Sciences
Information provided by:
Guang’anmen Hospital of China Academy of Chinese Medical Sciences
Study Description
Go to
Brief Summary:
Chinese prescriptions can inhibit viral replication according to the course of viral replication, and the effects is similar to the effect of HAART, and even better than the anti-viral and immune reconstitution of HAART due to its effect on improve immune system function. Over the past decades, many researchers have screened the effective Chinese medicines to treat AIDS.
Condition or disease
Intervention/treatment
Phase
Acquired Immune Deficiency Syndrome VirusHIV Infections
Drug: Fuzheng 2Drug: Placebo
Not Applicable
Detailed Description:
Researchers screened single Chinese herbs, some extract and the effective components of Chinese medicine and prescriptions. Some study the role of its anti-HIV, some study the role of its regulating immunization function. The former studies have shown that immunization 2 (Fuzheng 2) has wide effect on immune system and it can activate the reticuloendothelial system, macrophage phagocytes and lymphocyte transformation. And it can relieve disorders, imbalance of the immune system caused by HIV infection.
Study Design
Go to
Study Type :
Interventional (Clinical Trial)
Estimated Enrollment :
180 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Double (Participant, Investigator)
Primary Purpose:
Treatment
Official Title:
Research on Effect of TCM on Immune Reconstitution of HIV/AIDS Patients After HAART
Study Start Date :
September 2009
Estimated Primary Completion Date :
April 2010
Estimated Study Completion Date :
December 2010
Resource links provided by the National Library of Medicine
MedlinePlus related topics: HIV/AIDS
Arms and Interventions
Go to
Arm
Intervention/treatment
Active Comparator: Fuzheng 2
Immunity 2 (Fuzheng 2), 6.25g twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days.
Drug: Fuzheng 2
Immunity 2 (Fuzheng 2), 6.25g twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days.
Placebo Comparator: Placebo
Placebo, 6.25g twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days.
Drug: Placebo
Placebo, 6.25g twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days.
Outcome Measures
Go to
Primary Outcome Measures :
Secondary Outcome Measures :
Immune reconstitution efficiency [ Time Frame: 6 months ]
Viral load [ Time Frame: 6 months ]
Clinical symptoms and signs [ Time Frame: 6 months ]
KPS score [ Time Frame: 6 months ]
Quality of life score [ Time Frame: 6 months ]
Side effects of HAART [ Time Frame: 6 months ]
Safety evaluation [ Time Frame: 6 months ]
Economic evaluation [ Time Frame: 6 months ]
Eligibility Criteria
Go to
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years to 70 Years (Adult, Older Adult)
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Criteria
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations
Go to
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00974454
Contacts
Contact: Jie Liu, MD
8610-88001381
Locations
China, Beijing
Guang’anmen Hospital of China Academy of Chinese Medical Sciences
Recruiting
Beijing, Beijing, China, 100053
Contact: Jie WANG, MD 8610-88001381 dr.liujie@163.com
Sponsors and Collaborators
Guang’anmen Hospital of China Academy of Chinese Medical Sciences
Investigators
Study Chair:
Jie WANG, MD
Guang’anmen Hospital of China Academy of Chinese Medical Sciences
More Information
Go to
Responsible Party:
WANG, Jie/Professor, Guang’anmen Hospital of China Academy of Chinese Medical Sciences
ClinicalTrials.gov Identifier:
NCT00974454 History of Changes
Other Study ID Numbers:
09.07.16-1
First Posted:
September 10, 2009 Key Record Dates
Last Update Posted:
October 29, 2009
Last Verified:
September 2009
Keywords provided by Guang’anmen Hospital of China Academy of Chinese Medical Sciences:
AIDS
complementary therapies
treatment experienced
Additional relevant MeSH terms:
HIV Infections
Acquired Immunodeficiency Syndrome
Immunologic Deficiency Syndromes
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
The Effect of Combination of Traditional Chinese Medicine (TCM) and Highly Active Antiretroviral Therapy (HAART) on Immune Reconstitution of HIV/AIDS Patients
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00974519
Recruitment Status : Unknown
Verified September 2009 by Guang’anmen Hospital of China Academy of Chinese Medical Sciences.
Recruitment status was: Recruiting
First Posted : September 10, 2009
Last Update Posted : October 29, 2009
Sponsor:
Guang’anmen Hospital of China Academy of Chinese Medical Sciences
Information provided by:
Guang’anmen Hospital of China Academy of Chinese Medical Sciences
Study Description
Go to
Brief Summary:
Immunity 1 (Fuzheng 1) is composed of herbs which have tonic and detoxific function. The long-term clinical application has proved the safety and effect. It can improve the symptoms and signs in AIDS patients with the effective rate of 70% and can significantly improve the quality of life. It can also improve and stabilize immune function and inhibit viral replication. The basis study have shown that Immunity 1 (Fuzheng 1) can inhibit viral replication from multi-target, multi-link, enhance immune function, increase the secretion of IL-2, IFN-γ, participate in immune regulation effect, enhance NK cell activity, promote CD3+CD4+T cell proliferation and increase macrophage phagocytes capacity.
Condition or disease
Intervention/treatment
Phase
Acquired Immune Deficiency Syndrome VirusHIV Infections
Drug: Fuzheng 3Drug: Fuzheng 1Drug: Placebo
Not Applicable
Detailed Description:
Study Design
Go to
Study Type :
Interventional (Clinical Trial)
Estimated Enrollment :
180 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Double (Participant, Investigator)
Primary Purpose:
Treatment
Official Title:
Multi-center, Randomized, Double-blind, Placebo-controlled Clinical Trials on the Effect of Combination of TCM and HAART on Immune Reconstitution of HIV/AIDS Patients
Study Start Date :
September 2009
Estimated Primary Completion Date :
June 2010
Estimated Study Completion Date :
December 2010
Resource links provided by the National Library of Medicine
MedlinePlus related topics: HIV/AIDS
Arms and Interventions
Go to
Arm
Intervention/treatment
Active Comparator: Fuzheng 3
Immunity 3 (Fuzheng 3), 8.75g / twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days.
Drug: Fuzheng 3
Immunity 3 (Fuzheng 3), 8.75g / twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days.
Immunity 1 (Fuzheng 1) simulation agent, 8.75g / twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days.
Active Comparator: Fuzheng 1
Immunity 1 (Fuzheng 1), 8.75g / twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days.
Drug: Fuzheng 1
Immunity 1 (Fuzheng 1), 8.75g / twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days.
Immunity 3 (Fuzheng 3) simulation agent, 8.75g / twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days.
Placebo Comparator: Placebo
Placebo, 8.75g / twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days.
Drug: Placebo
Immunity 1 (Fuzheng 1) simulation agent, 8.75g / twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days.
Immunity 3 (Fuzheng 3) simulation agent, 8.75g / twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days.
Outcome Measures
Go to
Primary Outcome Measures :
Secondary Outcome Measures :
Immune reconstitution efficiency [ Time Frame: 6 months ]
Viral load [ Time Frame: 6 months ]
Clinical symptoms and signs [ Time Frame: 6 months ]
KPS score [ Time Frame: 6 months ]
Quality of life score [ Time Frame: 6 months ]
Side effect of HAART [ Time Frame: 6 months ]
Safety evaluation [ Time Frame: 6 months ]
Economic evaluation [ Time Frame: 6 months ]
Eligibility Criteria
Go to
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years to 70 Years (Adult, Older Adult)
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Criteria
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations
Go to
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00974519
Contacts
Contact: Jie Liu, MD
8610-88001381
Locations
China, Beijing
Jie, WANG
Recruiting
Beijing, Beijing, China, 100053
Contact: Jie WANG, MD 8610-88001381 dr.liujie@163.com
Sponsors and Collaborators
Guang’anmen Hospital of China Academy of Chinese Medical Sciences
Investigators
Study Chair:
Jie WANG, MD
Guang’anmen Hospital of China Academy of Chinese Medical Sciences
More Information
Go to
Responsible Party:
WANG, Jie/Professor, Guang’anmen Hospital of China Academy of Chinese Medical Sciences
ClinicalTrials.gov Identifier:
NCT00974519 History of Changes
Other Study ID Numbers:
09.07.16-2
First Posted:
September 10, 2009 Key Record Dates
Last Update Posted:
October 29, 2009
Last Verified:
September 2009
Keywords provided by Guang’anmen Hospital of China Academy of Chinese Medical Sciences:
ADIS
complementary therapies
Additional relevant MeSH terms:
HIV Infections
Acquired Immunodeficiency Syndrome
Immunologic Deficiency Syndromes
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Lactoferrin Treatment in HIV Patients
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01830595
Recruitment Status : Completed
First Posted : April 12, 2013
Results First Posted : September 18, 2018
Last Update Posted : October 18, 2018
Sponsor:
Jason Baker
Collaborator:
Ventria Bioscience
Information provided by (Responsible Party):
Jason Baker, Hennepin Healthcare Research Institute
Study Description
Go to
Brief Summary:
Our general goal is to evaluate the potential effectiveness of recombinant lactoferrin (1500mg bid) for reducing inflammation among HIV positive participants.
Condition or disease
Intervention/treatment
Phase
HIV Infection
Drug: Recombinant LactoferrinDrug: Placebo
Phase 2
Study Design
Go to
Study Type :
Interventional (Clinical Trial)
Actual Enrollment :
55 participants
Allocation:
Randomized
Intervention Model:
Crossover Assignment
Masking:
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
Recombinant Lactoferrin to Reduce Immune Activation and Coagulation Among HIV Positive Patients
Actual Study Start Date :
September 2014
Actual Primary Completion Date :
July 2017
Actual Study Completion Date :
January 2018
Resource links provided by the National Library of Medicine
MedlinePlus related topics: HIV/AIDS
Arms and Interventions
Go to
Arm
Intervention/treatment
Active Comparator: Recombinant Lactoferrin
Recombinant lactoferrin will be administered by mouth twice daily
Drug: Recombinant Lactoferrin
Placebo Comparator: Placebo
Matched placebo will be administered by mouth twice daily
Drug: Placebo
Outcome Measures
Go to
Primary Outcome Measures :
Number of Participants With at Least One Side Effect, Adverse Event, and Serious Adverse Event [ Time Frame: During 3 months on Lactoferrin or Placebo (and following washout period) ]
Self reported side effects and/or Division of AIDS (DAIDS) criteria will be used for grading adverse events (serious and non-serious)
IL-6 & D-dimer Score Changes From Baseline to 3 Months (or Month 5 to Month 8) [ Time Frame: 3 months (Baseline to Month 3 or Month 5 to Month 8) ]
The IL-6 & D-dimer score is defined as: 0. 33*log2 IL-6 + 0.16*log2 D-dimer, where IL-6 is measured in pg/mL and D-dimer in ug/mL. Since the biomarkers are on the log2 scale, associations of risk with the IL-6 & D-dimer score are interpreted as “HR(event) per doubling of IL-6 and D-dimer”, or “HR(event) per 20% increase in IL-6 and D-dimer”; the score itself is unitless.
Among the 3766 study participants for whom the score was developed, the min was -1.7, the max was 2.5.
Higher scores are worse.
Number of Participants Taking Medication as Assigned [ Time Frame: 3 months ]
Number of participants taking medication as assigned at 3 months
Other Outcome Measures:
Activated Monocyte Phenotype (CD16+) [ Time Frame: 3 months ]
The change in CD16+ monocyte subsets will be compared between active and placebo treatment phases. During both the active and placebo treatment phase, all relevant time points are used in calculation of change (i.e., baseline, month 1 and month 3 for phase 1; and similarly months 5, 6 and 8 for phase 2).
sCD163 [ Time Frame: 3 months ]
The change in blood levels of sCD163 will be compared between active and placebo treatment phases. During both the active and placebo treatment phase, all relevant time points are used in calculation of change (i.e., baseline, month 1 and month 3 for phase 1; and similarly months 5, 6 and 8 for phase 2).
Eligibility Criteria
Go to
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
40 Years and older (Adult, Older Adult)
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Criteria
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations
Go to
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01830595
Locations
United States, Minnesota
Hennepin County Medical Center
Minneapolis, Minnesota, United States, 55415
Sponsors and Collaborators
Jason Baker
Ventria Bioscience
Investigators
Principal Investigator:
Jason V Baker, MD, MS
Hennepin Healthcare Research Institute
Study Documents (Full-Text)
Documents provided by Jason Baker, Hennepin Healthcare Research Institute:
Study Protocol, Statistical Analysis Plan, and Informed Consent Form [PDF] March 25, 2015
More Information
Go to
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party:
Jason Baker, Associate Professor of Medicine, Hennepin Healthcare Research Institute
ClinicalTrials.gov Identifier:
NCT01830595 History of Changes
Other Study ID Numbers:
PCC-006
First Posted:
April 12, 2013 Key Record Dates
Results First Posted:
September 18, 2018
Last Update Posted:
October 18, 2018
Last Verified:
September 2018
Additional relevant MeSH terms:
HIV Infections
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Virus Diseases
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Immunologic Deficiency Syndromes
Immune System Diseases
Lactoferrin
Anti-Infective Agents
New Era Study: Treatment With Multi Drug Class (MDC) HAART in HIV Infected Patients (NewEra)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00908544
Recruitment Status : Completed
First Posted : May 27, 2009
Results First Posted : August 28, 2019
Last Update Posted : August 28, 2019
Sponsor:
MUC Research GmbH
Collaborators:
Merck Sharp & Dohme Corp.
AbbVie
Pfizer
German Center for Infection Research
Information provided by (Responsible Party):
MUC Research GmbH
Study Description
Go to
Brief Summary:
This is a multi-center, open-label, non-randomized proof-of-concept trial. Two cooperating HIV-specialized centres represented by Dr. med. Hans Jaeger and Prof. Dr. Johannes Bogner are planning to perform an IIT (investigator initiated trial) with the goal to eradicate HIV in N=40 HIV-infected patients with either primary infection or chronic infection and successful HAART (Highly Active Antiretroviral Treatment) of several years.
All patients will be started on a multi-drug HAART including two Nucleoside-Reverse-Transcriptase-Inhibitors (NRTI´s), one Protease-Inhibitor (PI), a CCR5-inhibitor and an Integrase-Inhibitor (INI). Decay of viral reservoirs like latently HIV-infected CD4+ T-cells will be monitored over time.
Condition or disease
Intervention/treatment
Phase
HIV Infections
Other: PHI-patientsOther: CHI-patients
Not Applicable
Show detailed description
Study Design
Go to
Study Type :
Interventional (Clinical Trial)
Actual Enrollment :
47 participants
Allocation:
Non-Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
NEW ERA STUDY - HIV and Eradication: A Multicenter, Open-label, Non-randomized Trial to Evaluate Treatment With Multi-drug Class (MDC) HAART and Its Impact on the Decay Rate of Latently Infected CD4+ T Cells Incl. Amendment 1.0
Actual Study Start Date :
May 15, 2009
Actual Primary Completion Date :
April 3, 2018
Actual Study Completion Date :
May 2018
Resource links provided by the National Library of Medicine
MedlinePlus related topics: HIV/AIDS
Arms and Interventions
Go to
Arm
Intervention/treatment
Experimental: PHI-patients
Patients with primary HIV infection (PHI) (see also “Eligibility”) are immediately treated with 2 NRTI + 1 PI/r + Maraviroc + Raltegravir
Other: PHI-patients
Treatment initiation with multi drug class (MDC) HAART. 2 NRTI + 1 PI/r + Maraviroc + Raltegravir
Experimental: CHI-patients
Patients with chronic HIV infection (CHI) and with suppressed plasma viral load for at least three years under continuous HAART (2 NRTI + 1 PI/r see also “Eligibility”) intensified by Maraviroc + Raltegravir
Other: CHI-patients
Treatment intensification of PI-based HAART with Maraviroc and Raltegravir. 2 NRTI + 1 PI/r + Maraviroc + Raltegravir
Outcome Measures
Go to
Primary Outcome Measures :
Combined Endpoint Including HIV RNA and HIV DNA [ Time Frame: Screening, month -3 (= pre-baseline only for CHI-patients), baseline, months 1, 3, 6 and then every 6 months until month 84 ]
The primary outcome measure (i.e. achievement of ‘eradication’) is a combined endpoint including cell-associated proviral DNA and plasma HIV RNA and is defined as undetectable cell-associated HIV DNA (copies per 10exp6 PBMC (peripheral blood mononuclear cells) and per 10exp6 CD4 cells) for at least 2 years (measurement by the French ANRS Group) combined with plasma viral load < 50 copies/ml for at least 5 years and undetectable plasma viral load (HIV RNA < 1 copy/ml, 1-copy assay) for at least 2 years.
Secondary Outcome Measures :
Mean Change in HIV DNA in PBMC (Month 36 and Month 84) [ Time Frame: Change from baseline at months 36 and 84 ]
Mean change (CI=95% Confidence Intervall) in HIV DNA copies/10exp6 PBMC (= peripheral blood mononuclear cells) from baseline, to evaluate the decay rates of latently infected cell reservoir.
Mean Change in HIV DNA in CD4+T Cells (Month 36 and Month 84) [ Time Frame: Change from baseline at months 36 and 84 ]
Mean change (CI=95% Confidence Intervall) in HIV DNA copies/10exp6 CD4+T cells from baseline, to evaluate the decay rates of latently infected cell reservoir.
HIV RNA <50 Copies/ml (Proportion) [ Time Frame: Baseline and at months 1, 3, 6 and then every 6 months until month 84 ]
Percentage of patients with Plasma HIV RNA <50 copies/ml at baseline and during follow-up
Median Change in HIV DNA in PBMC Over Time [ Time Frame: Change from baseline at months 1, 3, 6 and then every 6 months until month 84 ]
Median Change from baseline (IQR, interquartile range) in HIV DNA copies/10exp6 PBMC (= peripheral blood mononuclear cells), to evaluate the decay rates of latently infected cell reservoir.
Median Change in HIV DNA in CD4+T Cells Over Time [ Time Frame: Change from baseline at months 1, 3, 6 and then every 6 months until month 84 ]
Median Change from baseline (IQR, interquartile range) in HIV DNA in CD4+T cells, to evaluate the decay rates of latently infected cell reservoir.
Median Change in CD4+T Cells Over Time [ Time Frame: Change from baseline at months 1, 3, 6 and then every 6 months until month 84 ]
Median Change from baseline (IQR, interquartile range) in CD4+T cells/µl.
Median Change in Relative CD4+T Cells Over Time [ Time Frame: Change from baseline at months 1, 3, 6 and then every 6 months until month 84 ]
Median Change from baseline (IQR, interquartile range) in relative CD4+T cells/µl.
Median Change in CD4+/CD8+ Ratio Over Time [ Time Frame: Change form Baseline at months 1, 3, 6 and then every 6 months until month 84 ]
Median change in CD4+/ CD8+ ratio at baseline (IQR, interquartile range) and during follow-up
Median Change in CD8+T Cells Over Time [ Time Frame: Change from baseline at months 1, 3, 6 and then every 6 months until month 84 ]
Median Change from baseline (IQR, interquartile range) in CD8+T cells/µl.
Median Change in CD8+CD38+T Cells Over Time [ Time Frame: Change from baseline at months 1, 3, 6 and then every 6 months until month 84 ]
Median Change from baseline (IQR, interquartile range) in CD8+CD38+T cells/µl.
Absolute HIV DNA in PBMC [ Time Frame: Baseline and at months 1, 3, 6 and then every 6 months until month 84 ]
Absolute HIV DNA in PBMC (= peripheral blood mononuclear cells) from baseline (Median; IQR, interquartile range), to quantify the cell-associated latently infected reservoir size by visit and treatment Group.
Absolute HIV DNA in CD4+T Cells [ Time Frame: Baseline and at months 1, 3, 6 and then every 6 months until month 84 ]
Absolute HIV DNA in CD4+T cells from baseline (Median; IQR, interquartile range), to quantify the cell-associated latently infected reservoir size by visit and treatment Group.
Absolute CD4+T Cells [ Time Frame: Baseline and at months 1, 3, 6 and then every 6 months until month 84 ]
Median CD4+T cells/µl at baseline (IQR, interquartile range) and during follow-up
Relative CD4+T Cells [ Time Frame: Baseline and at months 1, 3, 6 and then every 6 months until month 84 ]
Median relative CD4+T cells/µl at baseline (IQR, interquartile range) and during follow-up
CD4+/CD8+ Ratio [ Time Frame: Baseline and at months 1, 3, 6 and then every 6 months until month 84 ]
Median CD4+/CD8+ ratio at baseline (IQR, interquartile range) and during follow-up
Absolute CD8+T Cells [ Time Frame: Baseline and at months 1, 3, 6 and then every 6 months until month 84 ]
Median CD8+T cells/µl at baseline (IQR, interquartile range) and during follow-up
Absolute CD8+CD38+T Cells [ Time Frame: Baseline and at months 1, 3, 6 and then every 6 months until month 84 ]
Median CD8+CD38+T cells/µl at baseline (IQR, interquartile range) and during follow-up
Eligibility Criteria
Go to
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years to 70 Years (Adult, Older Adult)
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Criteria
Inclusion Criteria:
For all patients:
HIV-infected patient
Age greater 18 years
No acute AIDS-defining disease or history of AIDS- defining disease
CD4-cell nadir above or equal 200 cells/µL
Hemoglobin greater 8 g/dl
Neutrophil count greater 750 cells/µL
Platelet count greater 50.000 cells/µL
AST/ALT below 5x upper limit of normal range
No evidence for drug intolerability
No prior use of an HIV integrase inhibitor or CCR5 antagonist
No presence of malignancy (requiring active treatment and malignancy within 5 years prior to enrolment (even if in complete remission)
No significant underlying disease (non-HIV) that might impinge upon disease progression or death
No history of alcohol or other substance abuse or other condition which in the opinion of the investigator would interfere with the patient compliance or safety.
Written informed consent
For males and premenopausal females use of acceptable methods of birth control during the entire study and for 6 weeks thereafter
No pregnancy (for premenopausal women: negative serum or urine pregnancy test within 48 hours prior to initiating study medications)
No breastfeeding
For chronically HIV-infected patients (CHI):
Continuous plasma viral load below 50 copies/ml for the preceding 36 months under HAART (two or less single viral load blips up to 500 copies/ml are allowed)
Stable HAART (for at least 3 months) prior to the Screening visit consisting of 2 NRTI + 1 PI
No history of virological failure
No documented resistance to PI and NRTI
CCR5-tropic virus
For patients with primary HIV infection (PHI):
Detectable plasma viral load
ELISA positive or negative and Western Blot negative or positive with less or equal 2 bands at screening visit
No primary resistance to PI´s and NRTI´s
CCR5-tropic virus
Exclusion criteria:
Evidence for drug intolerability or contraindication concerning any drug foreseen for MDC HAART
Documented HIV-1 resistance to PI and/or NRTI.
CD4 nadir <200/µL
Acute AIDS-defining disease or history of AIDS-defining disease
CHI: preceding virological failure
History of alcohol or other substance abuse or other condition which in the opinion of the investigator would interfere with the patient compliance or safety.
Any of the following abnormal laboratory test results in screening:
Presence of malignancy (requiring active treatment and malignancy within 5 years prior to enrolment (even if in complete remission)
Significant underlying disease (non-HIV) that might impinge upon disease progression or death
Prior use of any experimental HIV- Integrase-Inhibitor or CCR5-antagonist.
Patient is pregnant or breastfeeding, or expecting to conceive (within the duration of the study). Patient is expecting to donate eggs (within the duration of the study). Patient is expecting to donate sperm (within the duration of the study).
Contraindications for Maraviroc (Celsentri®) or Raltegravir (Isentress®) according to the respective summary of product characteristics (see also product informations attached to the protocol) (Hypersensitivity to the active substances or any of the excipients).
Contacts and Locations
Go to
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00908544
Locations
Germany
Onkology Karlsruhe
Karlsruhe, Baden-Wuerttemberg, Germany, 76135
Private Practice for Internal Medicine, Hematology and Oncology
Mannheim, Baden-Wuerttemberg, Germany, 68161
Private Practice Drs Ulmer/Frietsch/Mueller
Stuttgart, Baden-Wuerttemberg, Germany, 70197
Practice Dr. med. Lothar Schneider
Fürth, Bavaria, Germany, 90762
Private Practice Drs Pauli/Becker
Munich, Bavaria, Germany, 80331
MVZ Karlsplatz
Munich, Bavaria, Germany, 80335
University Munich University Hospital, Dept. of Infectious Diseases
Munich, Bavaria, Germany, 80336
ICH Study Center
Hamburg, Germany, 20354
Sponsors and Collaborators
MUC Research GmbH
Merck Sharp & Dohme Corp.
AbbVie
Pfizer
German Center for Infection Research
Investigators
Study Chair:
Hans Jaeger, MD
MUC Research GmbH
Study Chair:
Johannes Bogner, Prof., MD
University Munich, University Hospital, Dept. of Infectious Diseases,
Study Documents (Full-Text)
Documents provided by MUC Research GmbH:
Study Protocol and Statistical Analysis Plan [PDF] November 6, 2014
More Information
Go to
Publications of Results:
Other Publications:
Responsible Party:
MUC Research GmbH
ClinicalTrials.gov Identifier:
NCT00908544 History of Changes
Other Study ID Numbers:
MUC_NewEra_3.3
2008-002070-35 ( EudraCT Number )
4034932 ( Other Identifier: BfArM )
08101 ( Other Identifier: Bayerische Landesärztekammer )
ID 8879 ( Other Grant/Funding Number: Pfizer )
IISP #35576 ( Other Grant/Funding Number: MSD )
First Posted:
May 27, 2009 Key Record Dates
Results First Posted:
August 28, 2019
Last Update Posted:
August 28, 2019
Last Verified:
August 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD:
No
Keywords provided by MUC Research GmbH:
HIV-infection
Primary HIV-infection
Proviral DNA
Eradication
Multi drug class HAART
Additional relevant MeSH terms:
HIV Infections
Acquired Immunodeficiency Syndrome
Infection
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Virus Diseases
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Immunologic Deficiency Syndromes
Immune System Diseases
Slow Virus Diseases
2017-07-28 14:21
前几年，我在电脑玩物介绍过不少 Android 上的自动化工具，其中目前仍持续更新，还值得推荐的有：
但那时我独独漏掉 Tasker，而 Tasker 却是许多人心中最强大的 Android 自动化工具。
最近，看到「Tasker 5.0」推出，新版本有了焕然一新的界面，于是我便想说趁此机会来写一篇上手教学。
近年比较流行「IFTTT」或「Zapier」这类网络服务自动串连工具。或许熟悉网络服务的朋友，有看过我介绍：
它们的功能是当 A 服务出现什么资讯时，自动在 B 服务也加入同类资讯，例如自动把 Facebook 贴文导入 Evernote。
不过 Tasker 和 Agent、AutomateIt，不是上面那类工具，只是概念一样，就是「当 A 条件发生时，就触发 B 动作」。
「Tasker」主要是针对手机内置功能的自动化。例如它可以帮你在睡觉时自动手机静音，回到家里不再锁定手机，开车时自动启动导航地图，还能用内置功能自动开启省电模式等等，就看你要使用到什么程度。
尤其特别适合「常常会一直调整手机设定」的 Android 手机使用者，你只要利用「Tasker」设定好条件，那么它以后就能帮你在不同情况，自动调整你需要的设定，或是开启你需要的功能。
那 iOS 用户呢？有没有类似工具，也有，你可以试试看我之前介绍过的Workflow 史上最強 iOS App 自動化機器人上手教學與免費下載。
「Tasker」是付费软件，可以在 Google Play 上直接购买，以它强大的功能来说，价格不贵，只要新台币 100 元左右（约合人民币 22 元）。但如果你没用过，还不确定自己是否需要这个工具。那么你可以试试免费的试用版。
「Tasker」开发者在其官方网站上，有提供7 天试用版可直接下载。
乍看之下「Tasker」好像很复杂，是不是会很难用呢？其实它的上手逻辑是很简单的，困难点主要在于你可不可以想出「真正实用而有创意」的自动化流程。
要如何上手「Tasker」？只要思考一个问题就好：
你想在什么情境条件下，自动触发什么动作？
我就举个例子来示范，例如我最近开车都用「Google 地图导航」，但是我平常手机喜欢开静音（不要有任何干扰，也不要不小心干扰别人），所以我很需要一个自动化流程：「每次我打开 Google 地图时打开媒体音量，让导航有声音。但是我跳出 Google 地图时就关静音，避免干扰。」
这时候就可以利用「Tasker」解决上述需求，只要三个步骤！
首先一进入「Tasker」，会看到有一个「配置文件」的页面，这里其实就是让你「建立（要触发自动反应的）情境条件」。可以设定手机感应器、特殊时间点、插上特殊装置、电池状态等等各种条件。
例如以我前面所举的例子为例，我的条件就是：「当 Google 地图启动时」要触发某些行为。这时候我就点右下角的「+」，选择「应用程式」，选择「Google 地图」。
这样就在「配置文件」中加入了我要的「情境条件」，也就是「启动 Google 地图时」。
接着，我可以在第二个页面「任务」，加入我想触发的各种动作。「Tasker」之所以被认为很强大，就是因为它几乎可以触发手机上所有的装置功能，从音量、网络到各种设定。
回到我前面的例子，我想要触发的动作是「开启媒体音量」，于是我就在「任务」页面右下角点击「+」，加入「把媒体音量调整到 11」的动作。
有了「情境条件」，也有了「要触发的动作」，接着就把两个连在一起即可。
让「启动地图」这个配置，去连结刚刚建立的「开启媒体音量」任务。下图中则是我另外一个使用例子，当我开启TED 影片 app时，也自动触发开启媒体音量功能。
在「Tasker」中建立好上述条件与动作，实际执行的效果如下。
当我在手机上打开 Google 地图，媒体音量自动调整到 11，让我可以听到导航语音。当我跳出 Google 地图，媒体音量自动回到原本的静音状态。
这样就完成自动化流程，我就不用再自己动手调整了。
最后，为了让「Tasker」可以触发自动反应，你可能必须允许「Tasker」在后台运行，这样每次的条件触发才会顺利启动。
今天这篇文章，是「Tasker」的上手教学，我想用最简单的方法，让要试试看的朋友，知道「Tasker」这款工具并不难。当然，当你要进一步研究时，「Tasker」还有很多更进阶的设定，这就留待之后讨论了。
文章授权转自電腦玩物，原文链接：Tasker：Android 最强大自动化工具，最简单三步骤上手教学
本文由让手机更好用的 AppSo 精选推荐，关注公众号 AppSo，回复「效率神器」，获取为你精选的实用触发方案，让你轻松入门自动化神器 IFTTT。
2020年01月15日
在 2019 年的少数派年度盘点中，我们将「学会自动化魔法，少做无用功」作为一条能够帮你提高效率的年度建议。去年我们做了不少与自动化相关的内容和选题，但自动化对大多数用户而言依然有着不小的距离感。
因此在这篇文章中，我们请来少数派的作者和编辑分享他们的 Tasker 使用经验，希望能够消除你对 Tasker 这款自动化工具的抵触，更好地拥抱效率生活。
任务自动化最迷人的一点在于，当一切配置安顿好之后，只需要少许触发条件，「机器人」就悄悄地帮你完成了一切。你可能甚至意识不到它们的发生，自然而美好。
Tasker 作为 Android 平台上最优秀的任务自动化软件之一，可以帮助我们充分利用手机潜能（比如各类传感器），检测当前所处的状态并判断我们的意图，从而完成任务。从使用者的角度出发，我们甚至无需编写程序就能直接通过内置的交互界面做好任务配置。
下面展开讲讲我自己在用的几个常用配置：
非常简单也令人愉悦的配置：「当连接上指定的蓝牙设备时，开始播放音乐」。我主要使用的音乐播放设备是 Airpods 和蓝牙小音箱。戴上 AirPods、AirBattery 检测到后帮它连上蓝牙、音乐自然地流淌出来，音量正合适。
媒体音量调节
我有睡前戴耳机聆听音乐入睡的习惯，因为夜深人静，这个时候只需要很低的音量。所以我引入了这样的 Tasker 配置：「到了睡觉时间，调低媒体音量，30分钟后静音、终止音乐软件播放」。
说到睡眠，睡眠时间记录也是一个常用的场景。这里配合了 NFC 标签的使用，我把 NFC 标签贴在床头，每当到了睡觉时间 Tasker 唤起 NFC ，将手机靠近标签，这时 Tasker 里提前定义好的「入睡时间」变量便会记录下此刻的时间；早上清醒之后，再打一次卡，记录「起床时间」变量，后台计算出睡眠时间后，告诉我晚上睡了多久，是否满 8 个小时。同时添加一条记录到「睡眠记录」文件，每个周五的时候提醒我查看这周的睡眠状况。
睡眠记录与睡眠报告
仅仅使用了一些变量，就可以轻松记录睡眠。最重要的是，配合 NFC 标签这一物理打卡器，一般不会出现忘记的情况。
这个功能需要配合 Nova Launcher 启动器的 Swipe Up 和 AutoInput 软件。Nova Launcher 的 Swipe Up 支持软件图标上滑触发 Tasker 任务。所以我配置了上滑图标自动签到相关软件，Tasker 负责打开软件，AutoInput 负责自动完成点击任务。
网易云自动签到
还有一些简单的小任务：步数达到一个阈值时，晚些时候提醒拉伸放松；到家离家时问候以及提醒待办事项；电源不足提醒充电，充满电时提醒完成；打开 Instapaper 时启动横屏支持（本人的阅读习惯）；话费不足时打开充值界面……
Instapaper 的自动横屏支持
步数统计提醒
总之，Tasker 解放了一切不自由，发挥你的想象力使用它吧！
我从很早之前就开始使用 Tasker 了，在少数派的首篇文章也正是我自己使用 Tasker 一天的分享。
关联阅读：Tasker - 我与拥有它的生活方式
当时的文章截图
之后工作和学习上的需求不断新增，我在手机上制作的 Tasker 任务数量越来越多，复杂程度也越来越高。对比上一篇文章发表的时候，我惊奇地发现我制作的任务不仅拥有了更好看的 UI，而且已经能够完全覆盖生活和工作的方方面面。
于是在今年的 Power+ 中我用多篇文章给大家分享了自己探索的包括如何使用网络 API 来实现自动记录时间、如何利用读取 NFC 来实现物品管理等各种 Tasker 高级技巧与 Tasker 不断更新新版本后带来的新玩法，也在《Power+ 奏折 40》的桌面分享栏目中分享了自己目前任务的 UI 变化与新的任务，感兴趣的朋友也可以看看这篇文章。
更新的任务
上面提到我所制作的任务已经能够覆盖到生活工作的各种方面，其实主要是以下 6 个方面：
除此以外，我还帮助很多人制作了不同行业上使用的 Tasker 任务，比如营销行业的消息通知过滤提取与舆情邮件通知、房地产行业的房地产信息筛选报表，和特定房产推送通知甚至自动营销等都可以通过 Tasker 更加方便快捷实现。
部分任务列表
总而言之，限制 Tasker 能力的只有我们自己的想象力。
从上面相关文章的图片中大家可能也会发现，我制作自动化任务的时候非常注重 UI（或者说用户体验）——的确有很多任务，我在设计制作界面上花的时间比实现功能更多，既然 Tasker 给了我们创造自己界面的自由，那么我们就要好好利用它。
快递预测
我建议大家在开始接触 Tasker 了解简单功能的同时也可以接触一下应用本身提供的「场景」功能，用户创建场景后，可以使用 Tasker 提供的高自由度与丰富的组件类型来打造自己的界面，也可以给组件联动展示变量数据或者添加点击等触发事件，拥有自己打造的漂亮界面的成就感与体验是一个个操作叠起来最后单纯的靠对话框或者提示输出结果所比不了的。
所有的自动化应用都是为了解决你的设备在你满足设定的条件时自动运行你想要的动作这个需求的，而我可以说 Tasker 是其中的佼佼者，因为它最大的优点是拥有不同能力和不同级别需求的人群都能够在上面找到合适自己的入手角度和难度曲线。
为了某个小功能即装即用、直接导入别人做好的配置、不 Root 的情况下打造自己的任务、Root 设备之后打造自己的任务、甚至 Root 之后加上插件、本身不会编程和本身会编程……这些人群都能使用 Tasker 在自己的能力内，通过短时间学习找到制作符合自己需求任务的途径。这主要得益于 Android 开放的系统与热情的开发者们（虽然 Android 最近几个版本权限已经收紧到能和 iOS 一较高下的程度， Google 还是在 Play 日益严格的审核条件下给 Tasker 开了小灶以保持它的开放性），无论你只是想要在插入耳机时自动播放音乐，还是想要每天定时用 Python 结合机器学习分析预测黄金涨跌然后自动在支付宝上买入卖出，都能利用 Tasker 轻便地完成。
Tasker 场景搭建和利用本地网页构建场景
最后已经有很多人询问我付费教程的问题，为了解决大家不知道怎么轻松快速上手 Tasker，同时给大家分享更多我玩过用过的高级技巧，最近我会在少数派推出 Tasker 的入门与提高教程（起了个名字《Tasker 从入门到精通：打造真正的智能手机》，大家有更好听的也可以评论分享下），拥有教你如何快速上手和了解 Tasker 的基本内容操作，如何思考与实现常用的任务，又是如何利用 Tasker 实现更多高级操作等内容，包括：
感兴趣的朋友可以持续关注我的主页。
因为 Tasker 相对复杂、看上去有些距离的交互界面，我在使用 Android 设备的这几年时间里曾经好几次想要尝试这款自动化工具，但每次都在下载、安装后对着「熟悉而陌生」的主界面茫然无措。
2019 年发布的 Android 10 成为了一次契机。当时下定决心入坑 Tasker 的目的很简单：我想要一个更智能的自动暗色主题，弥补原生 Android 10 还没有这一设置的缺憾。好在在 Tasker 更新加入暗色主题支持的同时开发者也放出了一套近乎无脑的配置方案，直接导入即可使用。
借着这套导入的方案，我第一次认真研究起了 Tasker 这款工具：配置文件、任务、场景和变量分别对应了「触发条件」与「执行任务」中的哪些要素？如何在定制 ROM 中找到特定设置所对应的数值变化？任务编辑的过程中又是如何对变量进行赋值的？
在对开发者给出的模板配置进行拆解、调整和试错后，我算是完成了此前一直都没有勇气迈出的第一步。基于这套配置，我将自己的自动化暗色主题配置过程分享在了这篇文章里。
根据日落、日出时间自动开启、关闭的暗色主题
有了探索自动暗色主题切换的经验，我在之后的时间里也越来越多地尝试用 Tasker 解决日常生活中遇到的实际需求和问题，比如每天都要「走一遍」的睡前流程：
手机连上充电器放在枕边、关闭睡觉期间用不上的息屏显示（AOD）、开启飞行模式、打开蓝牙和 Wi-Fi、启动 Sleep as Android 开始睡眠追踪……
接触 Tasker 前我日复一日地重复着上面这个流程，从来没有思考过如何让它变得更简单：在我目前在用的配置方案中，我将时间段（每天晚上 12:00 至次日凌晨 3:00）和充电器状态（AC 交流充电）这两种状态作为睡眠追踪的触发条件，两个条件同时满足的前提下自动触发一系列后续任务，包括关闭息屏显示、开启飞行模式但保留 Wi-Fi 和蓝牙连接、将勿扰模式设定为「仅限闹钟」等等，最后借助 Sleep as Android 内建的 Tasker 接入，开始使用手环辅助进行睡眠追踪。
睡眠追踪配置方案
除了睡眠追踪，很多生活中需要重复、机械地进行手动切换的操作我都交给了 Tasker，比如网络切换：在连接到家里 Wi-Fi 时关闭某个「网络加速器」，在离开家、与家里的 Wi-Fi 断开后则自动启用这个「网络加速器」。
这种简单的小配置可以省下不少时间
而这些简单却实用的配置几乎都来源于最初对 Android 10 自动暗色主题的探索：理清自己的需求，分离触发条件与具体任务，然后通过对 Tasker 和第三方工具提供的接口进行摸索、试错，调校出一套适合自己的配置方案。有了实际要解决的问题之后，Tasker 显然没有我想象中的那么遥远。
我接触 Tasker 的时间已经有四年了，说来惭愧，时至今日我还是一个彻头彻尾的小白。
初识 Tasker 时，我也曾绞尽脑汁地设想过哪些场景能够自动化，甚至一度沉迷于在网络上搜索各种 Tasker 教程。当然最后教程看了不少，付诸实施的却没有几个，究其原因无非是没有发现自己的需求是什么，以至于教程看不懂也缺乏动力学习。
好在 Tasker 对于新手还算友好，内置的大部分触发条件摸索一下也能理解其含义，找到自己的真实需求后，便可以一步一步上手。
我的配置文件与任务
这里不妨从最简单的夜间模式说起：几年前的 Android 系统尚且不能实现自动开启夜间模式，于是「晚上自动调整亮度到最低，次日恢复」便成了我的第一个需求。围绕这一需求，我在 Tasker 当中设置了以固定时间点为触发条件的动作：晚上 10 点自动调整亮度到最低，次日 7 点恢复。接着，我又发现晚上的时候各类通知铃声过于扰人，因此，这个动作加长到了「晚上 10 点亮度最低+手机开启静音模式+媒体音量调整为两格」。
在 Google 为 Android 带来暗色模式后，我的动作也随之进行了扩展，Tasker 的优秀之处就在于开发者会不断地为它加入适应当前系统的新特性，以满足使用者不断增长的需求。当然，比起 这篇文章 当中的实现方式，我的思路还是过于简单了，有需要的朋友可以尝试一下文章当中更为高阶的方式。
对于系统相对原生的用户而言，短信验证码复制也是个颇为实际的需求。如果你和我一样对于自动化一窍不通，听到「正则表达式」、「脚本」等名词一头雾水，也不必要担心玩不转 Tasker。Tasker 允许用户分享已经设置好的配置，我们可以通过他人分享的文件乃至链接下载现成的配置。
短信验证码复制
通过酷安的评论区，我下载了热心网友分享的「短信验证码自动复制」这一配置，当短信当中含有验证码时，Tasker 会自动识别并复制验证码到剪切板，这对于使用类原生系统的我来说省事不少。
最后，由于在实际的手机使用过程中我经常会遇到插上耳机后还要特意去翻找音乐或视频应用的情况，因此为了省去翻找这一步骤，我利用 Tasker 内置的场景功能制作了一个小弹框。
当检测到插入耳机或者连接到我的蓝牙耳机就自动弹出选择框，方便我从常用的影音应用中选择自己想要的一个，单击 Spotify 图标打开 Spotify，长按则打开自带的音乐应用聆听本地音乐；单击 Netflix 图标打开 Netflix，长按则打开 Bilibili。当然，有时候我在插入耳机之前可能就已经打开了相应的应用，那么点击弹框的中间空白部分即可让弹框消失。事实上我们还可以为相应的图标位置添加双击操作，不过考虑到我实际上没有那么多应用需要用到耳机，也就不必要徒增记忆负担。
自制的媒体服务选择弹窗
这一弹框现在也变成了我检测自己耳机有没有插好或者连接成功的标志。那么这一土制的场景有没有缺陷呢？当然有，并且很大——横屏必崩，相信 Tasker 内一定有设置的方法，但是正如前文所说：我是小白，够用就好。
打开我手机上的 Tasker 后，只有寥寥几个动作，但是诸如插入耳机自动降低音量、回到家中自动连接自家 WiFi 这些细碎的事情都不再需要手动进行，我也渐渐习以为常，不必担心晚上粗心忘记开启静音被通知吵醒，也不必担心早上忘记打开 WiFi 而错过重要通知。
得益于 Tasker 的可繁可简，我们可以动动手就制造出实用的自动化动作，如今我已经不再执着于要将 Tasker 发挥出最大的价值，也不再艳羡大佬们各式各样的神奇操作。明白自己的需求是什么，动手调一调去实现就够了。
你是如何使用 Tasker 的，它又为你的生活带来了哪些改变？如果你在尝试 Tasker 的过程中遇到了问题，也欢迎在这篇文章的评论区留言交流。
题图来自Pixabay
关联阅读：
特惠、好用的硬件产品，尽在少数派sspai官方店铺🛒
Android 上最有趣的獨特 App 類型之一就是各式各樣的「自動化情境管理」工具。例如「MyProfiles 我的情境模式 Android 自動控制音量螢幕網路」可以偵測你的各種場所情境，讓 Android 手機自動在你開會時靜音、回家時開啟無線網路等等，省去一直手動重複調整相同設定，而可以讓手機更聰明的自動改變設定。
而最近發現一款更聰明、更簡單的免費自動化 Android App：「 Agent - do not disturb & more 」，這款 App目前可以做到：電池快沒電時自動開啟省電、睡覺時自動開啟勿擾模式、開會時自動關靜音、停車時自動記住停車位置、開車時開啟手機自動接通模式。
雖然「 Agent 」可能沒有其他自動化管理 App 的功能那麼多，但是相對的，「 Agent 」完全不需要設定，一安裝就有用，保證一般用戶也能上手，而其提供的上述自動化功能，也都是最切合大家日常需要的，非常值得試試看。
只要在 Android 手機上安裝這款「 Agent 」，預設就會啟動下面五個自動化功能，並且基本設定都已經調整好，大多數時候我們就能直接開始使用：
對於想要讓 Android 手機聰明完成自動化調整，但是懶得研究設定方法的朋友，這款「 Agent 」會是一個好選擇。
像是我目前使用的 HTC New One 有內建自動開啟省電模式，會在手機的電池電力過低時，自動關閉一些耗電的功能（延伸參考：不需安裝優化App， Android 新手機推薦用內建設定搞定優化）。
如果你的手機沒有這樣的自動省電設定，那麼「 Agent 」的自動省電會預設在電力剩下 10% 時，自動關閉你的同步、藍芽、無線網路，以及調暗你的螢幕。而當你手機開始充電時，就幫你自動回覆正常使用狀態。
「 Agent 」也幫我們預設好睡眠時自動開啟勿擾的功能，預設情況下會把每天下午 11 點到第二天早上 7 點當作睡覺時間，如果你的睡眠時間和預設不符合，也可以在這裡手動調整。
一旦睡覺時間到，「 Agent 」會自動把手機關靜音，並且拒絕任何來電、簡訊、通知鈴聲，讓我們可以好好睡覺，一直到起床時間，「 Agent 」才會自動還原手機原本的模式。
當然，有時候可能睡覺時我們也不能漏接一些重要的電話。
這時候「 Agent 」也提供了手動進階設定功能，我們可以指定「哪些人打來的電話」會有來電鈴聲，或者是對方如果在 5 分鐘內連續打來兩次電話（可能真的有急事），那麼就想起來電鈴聲。
是不是很聰明？
「 Agent 」還可以在「 Parking 」模式中自動記住你停車的位置，更棒的是，我們什麼都不需要設定，只要你的手機有正常的定位功能即可（參考：手機 GPS定位 WiFi定位 怎樣省電精準？地圖實測比較心得）。
「 Agent 」會自動偵測我們的移動速度，判斷我們什麼時候在開車、什麼時候停車、什麼時候改成走路，於是「 Agent 」就能偵測出我們「停車下車」的位置，並且自動在地圖上標註出我們把車子停在哪裡。
在清單中可以看到幾點幾分的停車定位，如果後來找不到之前停車的地方，利用這個清單，就能開啟地圖幫你導航到停車處！
我測試這個功能好幾次，每次都很準確，不輸「Google 定位紀錄帶你解鎖世界地圖，回想一生旅行記憶」，很值得試試看。
「 Agent 」預設會讀你 Android 手機上的行事曆，判斷出裡面設定為忙碌狀態的會議行程，並且在會議時間到達時，自動把手機切換到靜音模式，讓你不會在開會時被干擾到，也讓你不會忘記在開會前關手機。
而會議時間結束後，就會幫你自動還原。
更進一步的，在「 Agent 」的進階設定中，還可以指定幾點到幾點、一週內的哪幾天，要開啟這個開會靜音的行事曆自動偵測功能。
最後一個「 Agent 」的神奇自動設定，就是偵測到妳開車時，會幫你把手機調整成自動接通的模式，但是這個模式只有對真正的開車族有用，而且需要藍芽設定會比較準確，「 Agent 」可以在偵測、連結到車上的藍芽設備時，自動判斷你開始開車了，才開啟開車模式。
不過這個模式對我來講不需要，所以我將這個模式關閉，而使用「 Agent 」的其他四種模式。
「 Agent 」提供的開會靜音、睡眠勿擾、停車定位、自動省電，都是一般用戶常常會用到的功能，將這些動作自動化，讓我們省下許多麻煩，而且「 Agent 」還完全不需要設定，一安裝就能自動啟動這些功能，對一般用戶來說非常好上手，值得試試看。
我對於 Android 上的各種「自動化 App」很有興趣。回想我們自己的智慧型手機使用情況，你會不會常常需要進行重複的手機操作，例如：
如果要一直「自己手動」切換開關，智慧型手機似乎就不夠智慧了。所以像是「 AutomateIt 」這樣的 App 就能大量節省反覆進行相同操作的時間，透過建立自動規則，手機就會在特定情況自動調整或啟動功能。而且「 AutomateIt 」還擁有中文介面與免費版本。
「 AutomateIt 」有區分付費和免費版本，一開始用戶可以先試試看免費版，如果覺得適合自己，或是需要進階功能，再購買付費版即可。
進入「 AutomateIt 」 App，可以看到主畫面上有「我的規則」儲存你自己建立的自動化規則，以及「規則市集」查看別人建立的規則。若是一開始你不知道建立什麼樣的規則對自己有幫助，可以到「規則市集」參考。
在「規則市集」中除了可以查看別人怎麼建立規則，也可以將別人想到的好規則下載到「 AutomateIt 」中使用。這是我覺得「 AutomateIt 」很不錯的一點，增加了使用上的方便性，不用自己去想規則要怎麼建立比較好，直接使用熱門、常用規則即可。
例如我喜歡別人建好的：「打開地圖就開 GPS」、「關掉地圖就關閉 GPS 」自動規則，直接下載規則。
這樣一來就只有真的需要定位的 Google 地圖打開時才會開啟 GPS，關閉地圖後也會自動把 GPS 關閉，而像是打開臉書等社群 App 就不會浪費不必要的 GPS 電力了。
你也可以自己在「 AutomateIt 」中建立規則，過程很直覺：
這樣就能建立一個「每當 XXX 發生時」，就讓手機「自動執行 XXX」，一些瑣碎但可能會重複執行的動作，都可以用這類自動化工具來完成，讓我們不用再自己動手操作，就能節省大量時間了！
「 AutomateIt 」 Android App：https://play.google.com/store/apps/details?id=AutomateIt.mainPackage
類似工具推薦：
為什麼你會想要重複切換不同手機設定？可以參考：
「IFTTT」是一個頗受好評的「網路自動連結」服務，什麼是網路自動連結？例如我自己在 IFTTT 上使用了一份「配方（菜單、 Recipes ）」，內容是「只要我在 Facebook 發表圖文訊息，那麼這份圖文訊息就會自動轉存到我的 Evernote 筆記」，這滿足了我把 A 服務內容串連到 B 服務的需求，並且我不用自己轉貼， IFTTT 可以自動幫我完成上述動作。
IFTTT 讓各個網路服務之間不再靜態分佈，可以把不同網路串連成「行動」，「如果」 A 服務發生什麼事情，「那麼」 B 服務就做出什麼反應。
從一方面來看 IFTTT 讓「不會寫程式」的一般用戶也可以完成上面那樣神乎其技的配套，但另一方面來說 IFTTT 博大精深，仔細玩下去會發現很多可以自訂的細節，可是畢竟這是國外服務，有些自動串連的機制不一定那麼適合台灣用戶（例如對中文支援不完美）。
幸好，最近 IFTTT 開始朝行動裝置邁進，接連推出了 IFTTT 的 iPhone、 iPad、 Android 版本，讓網路服務也可以去觸發我們身邊行動裝置上的反應（或是反過來），而這樣的演進我覺得更貼近個人的生活層面應用，所以我決定分成幾篇來好好介紹 IFTTT 這個的服務。今天這篇就先從以 App 來入門開始。
這邊我以 IFTTT 的 Android 版介面作為介紹，因為 App 版本的介面更直覺，可以讓我們更快了解 IFTTT 的使用概念，其他版本的用法也大同小異，大家可以延伸參照。
第一次打開 IFTTT App ，可以看到這個服務的簡單介紹，在 IFTTT 中給予用戶一個創造「如果怎樣就會怎樣」的能力，我們只要填入自己需要的服務，就可以創造「連鎖反應」。
「配方（菜單、 Recipes ）」，就如同它的名字所表示的一樣，是「料理」不同網路服務的「別人提供的方法」，在 Android 版中點擊右上方的「料理」按鈕，就可以看到自己已經啟動的「配方（ Recipes ）」，繼續點擊右上方的「眼鏡」按鈕，可以查看他人提供的配方。
如果我拍了一張新照片就自動換成手機桌布。
如果我在Facebook上張貼照片就自動把照片存入 Evernote。
這些都可以在「 Browse 」中找到他人提供的固定配方，而我們只要在 IFTTT 裡啟動這些配方，就能完成配方裡設定好的自動化流程。
而在瀏覽這些「配方（菜單、 Recipes ）」時，可以依據特色配方、熱門配方等排行榜，讓出學者快速找到好用的配方，直接試試看效果。
你可以在 IFTTT App 中搜尋上述對應的配方名稱（看你使用 Android 或 iOS ），或是直接點擊配方的網址來啟動。
打開這份配方（ Recipe ）後，可以看到配方的功能描述，確認後按下〔 Use Recipe 〕。
因應這份配方是要達成「如果明天下雨，請在今天提醒我」，所以首先會要求我們設定好自己想要偵測的城市地點，輸入地點並找到地點後，在天氣設定畫面按下〔 Activate 〕。
這邊就做一個簡單的示範，同樣在配方（ Recipe ）頁面中點擊「+」，進入自訂配方的畫面，這時候會看到 IFTTT 的基礎命令「如果（if）怎樣，那麼就會（then）如何」，我們只要自己在「如果」、「就會」的後面加上自己設定的行動即可。
在「 if 」後面點擊「 + 」，設定「如果」的條件，這裡可以看到所有可以當作條件的網路服務、手機功能，在其中選擇「 Date & Time 」，點擊「 Every day at 」。
第一次啟動時間功能時，會要求啟動查詢時間的權限，按下繼續後，會要求我們設定一個命令的時間，這裡調整成晚上 11 點即可。
透過上面的 IFTTT 基本介面、添加別人製作好的配方、自己設定一份新配方，我們就可以快速練習 IFTTT 的基本功能，有興趣的朋友，則可以繼續深入研究看看，會發現有很多有趣強大的應用，尤其發揮創意想像力，說不一定你可以讓網路更聰明自動化喔！
延伸閱讀，Android 其他自動化工具：
我在電腦玩物曾經介紹過一個叫做「 IFTTT 」的服務，他的功能是在兩個不同的雲端服務之間創造自動化工作，例如「IFTTT Android iOS 入門教學：如果明天下雨請今日提醒我」、「用 LINE 即時通訂閱對你最有價值的網站新文章」。
而這幾年在國外還有另一個更進階的知名服務叫做：「Zapier」，他可以創造出許多生產力工具之間更複雜的連動，例如像是：
跟我一樣使用 Evernote 與 Google 日曆做任務管理的朋友，可以試試看用「 Zapier 」來滿足兩個服務之間自動連動的需求，而且經過我一段時間的測試，這樣的自動連動頗為穩定，這篇文章我也把設定步驟寫成一篇教學。
不用擔心會很難，雖然「 Zapier 」比較專業，但設定步驟其實也非常簡單，甚至套用基本模板後，只要跟著下一步完成設定即可。
那麼先讓我介紹第一個方法：
假如我準備好了一個「Esor的時間管理課程」的 Evernote 筆記，上課日期是 6/24 ，於是我在筆記加上 6/24 的時間提醒，這時候，「 Zapier 」將會在 Google 日曆的 6/24 上新增這個筆記的行程，附上筆記的連結。
怎麼做到？首先請你先申請一個「Zapier」帳號，然後你可以搜尋要建立 Evernote 與 Google 日曆兩種服務之間的自動化工具，並找到別人已經建立好的模板來套用，這邊我已經幫大家找到可以使用這個模板：「當 Evernote 筆記加上時間提醒，就自動匯入成 Google 日曆新行程」。
點開我前面提供的模板網址，然後在最下方按下「 Create this Zap 」。
接著按照預設，勾選當 Evernote 筆記有加上時間提醒就啟動功能，按下「 Continue 」繼續。
當然，下一步我們要認證自己的 Evernote 帳號後繼續。
接著選擇在哪個記事本裡的 Evernote 筆記加上時間提醒後，會觸動功能。
如果不選，就是所有筆記都會觸動。
下一步，就換成認證 Google 日曆帳號。
認證好 Google 日曆，接著就要設定如何把 Evernote 筆記的內容，匯入到 Google 日曆行程。
首先在「 Calendar」 ，選擇加上提醒的筆記要匯入哪一個行事曆。
接著在「 Start Date & Time 」，選擇根據 Evernote 的時間提醒，在 Google 日曆的相應時間加上行程。
還要在「 End Date & Time 」，選擇行程的結束時間，這時候要使用語法，例如在 Evernote 提醒時間後面「 +1h」（記得要空一格），就表示這個行程一個小時後結束。
下方還可以做更多進階設定，例如用筆記標題當作 Google 日曆行程的名稱，以及要在 Google 行程的「說明（ Desciption ）」裡插入哪些筆記內容，我建議可以選下面兩個：
很簡單，一步一步來，這樣就設定完成了！「 Zapier 」預設每 15 分鐘會自動檢查一次，如果有發現新的加上提醒的筆記，就會在日曆新增行程。
回到「 Zapier 」的控制台，你可以看到自己目前啟動的所有自動工作菜單。
實際測試，我在 Evernote 某一則已經建立一段時間的筆記加上新的「時間提醒」（參考教學：Evernote 活用「提醒事項」教學，解決七大時間管理問題），等個十幾分鐘，就看到 Google 日曆上的那一個時間，出現我要的行程囉！
另一個方法，則是反過來，如果我在 Google 行事曆上建立一個新的行程，就讓這個行程自動在 Evernote 建立一則筆記，例如：
我下週五有一個會議，在 Google 日曆上建立會議行程，於是自動在 Evernote 新增這一次會議的會議筆記，筆記裡有相關的時間地點與說明資訊。（參考：如何建立有效會議記錄？ Evernote 會議筆記範本格式心得）
如何做到？利用「 Zapier 」的「把新的 Google 日曆行程匯入到新 Evernote 筆記」模板即可。
同樣的先認證 Google 日曆帳號，並指定要用哪一個行事曆的行程。（可參考：用 Google 日曆和家人一起管好家庭計劃，強化感情的7個技巧）
接著認證 Evernote 帳號，然後指定新的行程筆記要匯入哪一個記事本。
其他大致上維持預設即可，也就是用行程名稱當做筆記標題，把行程的時間地點與說明匯入成筆記內文。
下面就是從 Google 日曆自動匯入的 Evernote 筆記。
最近， Evernote 官方也在「Evernote 網頁版」測試一個「把 Google 日曆匯入成會議筆記」的新功能，有興趣的朋友也可以去網頁版試試看。
熟練上述的方法後，如果覺得預設模板沒有自己想要的，也可以在「 Zapier 」中利用「 Make A ZAPI 」，來建立自己全新的自動化菜單。
當然除了 Evernote 和 Google 日曆的連動，還有許多服務可以設定，有興趣的朋友可以好好研究看看「 Zapier 」。
最後要注意的是，如果是使用「 Zapier 」免費版，最多可以規劃「五個」自動化工作流程，每個月「最多觸發 100 次的自動化連動」。
延伸閱讀相關文章：
「 Zapier 」網站
轉貼本文時禁止修改，禁止商業使用，並且必須註明來自電腦玩物原創作者 esor huang（異塵行者），及附上原文連結：Zapier 教學：讓 Evernote 筆記與 Google 日曆自動連動好方法
缺失模块。
1、请确保node版本大于6.2
2、在博客根目录（注意不是yilia根目录）执行以下命令：
npm i hexo-generator-json-content --save
3、在根目录_config.yml里添加配置：
jsonContent:
meta: false
pages: false
posts:
title: true
date: true
path: true
text: false
raw: false
content: false
slug: false
updated: false
comments: false
link: false
permalink: false
excerpt: false
categories: false
tags: true